{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-23-000138","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.086233+00:00","generated_at":"2026-06-08T23:52:51.723649+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Agios Q3: PYRUKYND rev $7.4M; first patient dosed in Phase 3 sickle cell; net loss $91.3M","bullets":["PYRUKYND net revenue $7.4M in Q3 2023 (+10% QoQ); 100 patients on therapy, 160 completed enrollment forms.","First patient dosed in Phase 3 portion of RISE UP pivotal study of mitapivat in sickle cell disease.","Completed enrollment in Phase 3 ACTIVATE-kidsT; >50% enrolled in Phase 3 ACTIVATE-kids for pediatric PK deficiency.","Net loss $91.3M in Q3 2023 vs $81.7M in Q3 2022; cash $872.4M as of Sep 30, 2023, funding into 2026.","Topline data for AG-946 in LR-MDS expected by year-end 2023; Phase 3 thalassemia data in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-23-000138","json":"https://secwatch.observer/filing/0001439222-23-000138.json","markdown":"https://secwatch.observer/filing/0001439222-23-000138.md","text":"https://secwatch.observer/filing/0001439222-23-000138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/0001439222-23-000138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/agio-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:52:51.723649+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"31947ca1cca3bc026aee4476d97ed18faa44120e","claim":"AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2023 results: revenue $7.4 million, net income $91.3 million net loss.","evidence_excerpt":"Data Readouts in Two Phase 3 Trials of Mitapivat in Thalassemia Next Year and Topline Data for AG-946 in LR-MDS by Year-end 2023 – – U.S. PYRUKYND ® (mitapivat) Net Revenue of $7.4 Million in Q3; Cash, Cash Equivalents and Marketable Securities of $872.4 Million as of September 30, 2023 – CAMBRIDGE, Mass., November 2, 2023 -- Agios Pharmaceuticals, Inc. (Nasdaq:","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922223000138/0001439222-23-000138-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$7.4 million"},{"label":"Net income","value":"$91.3 million net loss"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}